Search Results - "NEYLAN, J. F"

Refine Results
  1. 1

    Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine by NEYLAN, J. F

    Published in Transplantation (27-02-1998)
    “…Results of a multicenter, randomized, clinical trial demonstrated that tacrolimus was more effective than cyclosporine in preventing acute rejection in…”
    Get full text
    Journal Article
  2. 2

    An open-label, concentration-ranging trial of FK506 in primary kidney transplantation : A report of the United States Multicenter FK506 Kidney Transplant group by LASKOW, D. A, VINCENTI, F, NEYLAN, J. F, MENDEZ, R, MATAS, A. J

    Published in Transplantation (15-10-1996)
    “…This was a multicenter, open-label, concentration-ranging trial of FK506 and cyclosporine in 120 patients undergoing primary cadaveric kidney transplant…”
    Get full text
    Journal Article
  3. 3

    Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients : a randomized controlled trial by HIBBERD, P. L, TOLKOFF-RUBIN, N. E, CONTI, D, STUART, F, THISTLETHWAITE, J. R, NEYLAN, J. F, SNYDMAN, D. R, FREEMAN, R, LORBER, M. I, RUBIN, R. H

    Published in Annals of internal medicine (01-07-1995)
    “…To determine whether preemptive ganciclovir therapy administered daily during antilymphocyte antibody therapy can prevent cytomegalovirus disease in renal…”
    Get full text
    Journal Article
  4. 4

    One-year follow-up of an open-label trial of FK506 for primary kidney transplantation : A report of the U.S. Multicenter FK506 Kidney Transplant Group by VINCENTI, F, LASKOW, D. A, NEYLAN, J. F, MENDEZ, R, MATAS, A. J

    Published in Transplantation (15-06-1996)
    “…Patients undergoing primary cadaveric kidney transplantation were followed for 1 year as part of a phase II, multicenter, open-label concentration-ranging…”
    Get full text
    Journal Article
  5. 5

    The Effect of Race on Access and Outcome in Transplantation by Kasiske, Bertram L, Neylan, John F, Riggio, Robert R, Danovitch, Gabriel M, Kahana, Lawrence, Alexander, Steven R, White, Martin G

    Published in The New England journal of medicine (31-01-1991)
    “…THE American Society of Transplant Physicians directed its Patient Care and Education Committee to examine the issue of racial inequality in transplantation…”
    Get full text
    Journal Article
  6. 6

    Assessment of the frequency and costs of posttransplantation hospitalizations in patients receiving tacrolimus versus cyclosporine by Neylan, JF, Sullivan, EM, Steinwald, B, Goss, TF

    Published in American journal of kidney diseases (01-11-1998)
    “…We assessed the frequency and costs of hospitalizations in patients receiving tacrolimus (FK506) compared with patients receiving cyclosporine A for…”
    Get full text
    Journal Article
  7. 7

    The role of tacrolimus in adult kidney transplantation: a review by Laskow, D A, Neylan, 3rd, J F, Shapiro, R S, Pirsch, J D, Vergne-Marini, P J, Tomlanovich, S J

    Published in Clinical transplantation (01-12-1998)
    “…The use of tacrolimus (FK506) in adult kidney-transplant recipients has been the subject of a number of single- and multi-center studies. This review article…”
    Get more information
    Journal Article
  8. 8
  9. 9

    The evaluation of candidates for renal transplantation. The current practice of U.S. transplant centers by Ramos, E L, Kasiske, B L, Alexander, S R, Danovitch, G M, Harmon, W E, Kahana, L, Kiresuk, T J, Neylan, J F

    Published in Transplantation (27-02-1994)
    “…The criteria for acceptance of candidates for renal transplantation varies throughout the United States. The Patient Care and Education Committee of the…”
    Get more information
    Journal Article
  10. 10

    Race and sex differences in the identification of candidates for renal transplantation by Soucie, J M, Neylan, J F, McClellan, W

    Published in American journal of kidney diseases (01-05-1992)
    “…The availability of renal transplantation to individuals with end-stage renal disease (ESRD) is an issue of considerable concern. The role of age, race, sex,…”
    Get more information
    Journal Article
  11. 11

    Immunosuppressive therapy in high-risk transplant patients. Dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients by Neylan, J F

    Published in Transplantation (15-11-1997)
    “…Numerous studies have demonstrated that renal allograft survival is reduced in African-Americans (AAs). This posthoc racial subgroup analysis (AAs vs. non-AAs)…”
    Get full text
    Journal Article
  12. 12
  13. 13

    The influence of duffy blood group on renal allograft outcome in African Americans by AKALIN, Enver, NEYLAN, John F

    Published in Transplantation (15-05-2003)
    “…African American patients demonstrate higher rates of acute allograft rejection and lower kidney-graft survival compared with white patients. Duffy antigen…”
    Get full text
    Conference Proceeding Journal Article
  14. 14

    Microchimerism and rejection in clinical transplantation by Elwood, E T, Larsen, C P, Maurer, D H, Routenberg, K L, Neylan, J F, Whelchel, J D, O'Brien, D P, Pearson, T C

    Published in The Lancet (British edition) (10-05-1997)
    “…Haemopoietic microchimerism has been identified in recipients of solid-organ transplants and is thought by some to be critical for the development and…”
    Get more information
    Journal Article
  15. 15

    Gene expression analysis in human renal allograft biopsy samples using high-density oligoarray technology by AKALIN, Enver, HENDRIX, Rose C, POLAVARAPU, Rathna Giri, PEARSON, Thomas C, NEYLAN, John F, LARSEN, Christian P, LAKKIS, Fadi G

    Published in Transplantation (15-09-2001)
    “…High-density oligoarray technology is a novel method for screening the expression of thousands of genes in a small tissue sample. Oligoarray analysis of genes…”
    Get full text
    Journal Article
  16. 16

    Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3 : A randomized, double-blind placebo-controlled study by VINCENTI, F, DANOVITCH, G. M, NEYLAN, J. F, STEINER, R. W, EVERSON, M. P, GASTON, R. S

    Published in Transplantation (27-02-1996)
    “…The use of OKT3 as an immunosuppressive agent is accompanied by increased cytokine production and constellation of side effects collectively termed cytokine…”
    Get full text
    Conference Proceeding Journal Article
  17. 17

    Payment for Immunosuppression After Organ Transplantation by Kasiske, Bertram L, Cohen, David, Lucey, Michael R, Neylan, John F, for the American Society of Transplantation

    “…Dramatic improvements in organ transplantation have meant that a growing number of patients must take expensive immunosuppressive medications for the rest of…”
    Get full text
    Journal Article
  18. 18

    Ureteral obstruction due to calculi in the early postoperative period in renal cadaveric transplantation: a case report and discussion of ureteral obstruction in the renal transplant patient by Heron, S P, O'Brien, 3rd, D P, Whelchel, J D, Neylan, J F

    Published in The Journal of urology (01-04-1995)
    “…We report a case of obstruction secondary to multiple ureteral calculi on postoperative day 3 after cadaveric renal transplantation. Treatment consisted of…”
    Get more information
    Journal Article
  19. 19

    Hypertension after renal transplantation by First, M R, Neylan, J F, Rocher, L L, Tejani, A

    “…Hypertension is a frequent complication after organ transplantation in both children and adults and is a significant risk factor for the development of…”
    Get full text
    Journal Article
  20. 20

    Conclusions: the maintenance of allograft acceptance by Rodey, G E, Neylan, 3rd, J F

    Published in Clinics in laboratory medicine (01-09-1991)
    “…This article summarizes all of the findings of the authors in this issue who examined various laboratory procedures used to implement and monitor…”
    Get more information
    Journal Article